Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein with antiangiogenic properties. A non-membrane associated splice variant of VEGF receptor 1 (Flt …

2016年1月7日 · We designed the study to derive and validate a cutoff point of the sFlt-1:PlGF ratio for the prediction of the short-term absence or presence of preeclampsia, in a two-phase …

sFlt-1 (sVEGFR-1) is an antiangiogenic factor expressed as an alternatively spliced variant of VEGFR-1 that lacks both the transmembrane and cytoplasmic domains. sFlt-1 binds VEGF …

2021年8月15日 · One driving factor for developing preeclampsia—a pregnancy disorder, often associated with poor spiral artery (SpA)-remodeling and fetal growth restriction—is the anti …

The anti-angiogenic factor, soluble fms-like tyrosine kinase 1 (sFlt-1) and the pro-angiogenic factor, placental growth factor (PlGF), can be measured in plasma and serum and are usually …

2020年7月27日 · Preeclampsia is characterized by angiogenic imbalance (AI), sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) is useful for its diagnosis and prediction …

2025年2月18日 · sFlt-1 and PlGF are key biomarkers in the formation of blood vessels during pregnancy. However, an angiogenic imbalance of these key biomarkers has been proven to …

The Elecsys® sFlt-1/PlGF ratio is an FDA-cleared test that provides objective data to complement standard clinical assessment and laboratory evaluation in risk stratification for preeclampsia …

Recently, sFlt-1 has emerged as a new marker for early diagnosis and disease surveillance of angiogenesis-related diseases. However, few comprehensive reviews focus on the …

Soluble fms-like tyrosine kinase-1 (sFlt-1) is a vascular endothelial growth factor and antagonist of placental growth factor (PlGF) that causes vasoconstriction and endothelial damage,...